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Abstract 
Background: Studies have indicated that bone marrow stromal cell (BMSC) administration is a promising approach 
for stroke treatment. For our study, we chose sodium ferulate (SF) and n-butylidenephthalide (BP) combined with 
BMSC, and observed if the combination treatment possessed more significant effects on angiogenesis and neurogen-
esis post-stroke.
Methods: We established rat permanent middle cerebral artery occlusion (MCAo) model and evaluated ischemic 
volumes of MCAo, BMSC, SF + BP, Simvastatin + BMSC and SF + BP + BMSC groups with TTC staining on the 7th 
day after ischemia. Immunofluorescence staining of vascular endothelial growth factor (VEGF) and brain derived 
neurotrophic factor (BDNF), as well as immunohistochemistry staining of von Willebrand factor (vWF) and neuronal 
class III β-tubulin (Tuj1) were performed in ischemic boundary zone (IBZ), furthermore, to understand the mechanism, 
western blot was used to investigate AKT/mammalian target of rapamycin (mTOR) signal pathway in ischemic cortex. 
We also tested BMSC derived-VEGF and BDNF expressions by western blot assay in vitro.
Results: SF + BP + BMSC group obviously decreased infarction zone, and elevated the expression of VEGF and the 
density and perimeter of vWF-vessels as same as Simvastatin + BMSC administration; moreover, its effects on BDNF 
and Tuj1 expressions were superior to Simvastatin + BMSC treatment in IBZ. Meanwhile, it showed that SF and BP 
combined with BMSC treatment notably up-regulated AKT/mTOR signal pathway compared with SF + BP group and 
BMSC alone post-stroke. Western blot results showed that SF and BP treatment could promote BMSCs to synthesize 
VEGF and BDNF in vitro.
Conclusions: We firstly demonstrate that SF and BP combined with BMSC can significantly improve angiogenesis 
and neurogenesis in IBZ following stroke. The therapeutic effects are associated with the enhancement of VEGF and 
BDNF expressions via activation of AKT/mTOR signal pathway. Furthermore, triggering BMSC paracrine function of SF 
and BP might contribute to amplifying the synergic effects of the combination treatment.
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(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
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Background
Bone marrow stromal cells (BMSCs) have been recog-
nized as a distinguished candidate for ischemic stroke 
treatment in terms of their multi-potentiality [1]. Numer-
ous studies suggested BMSC administration could 
enhance endogenous neurogenesis and angiogenesis; 
moreover, part of them showed neuronal and endothe-
lial morphologies in the ischemic boundary zone (IBZ) 
post-stroke [2–6]. Because neurogenesis would directly 
replace dead neurons and angiogenesis would result 
in new blood vessel formation, which might obviously 
increase oxygen, glucose, nutrients supplement and 
neural stem cells (NSCs) migration to IBZ, evidence 
suggested that neurogenesis and angiogenesis played a 
central role in the neurological functional recovery after 
stroke [7]. A recent research demonstrated neurogen-
esis was coupled with angiogenesis, and neurorestorative 
therapy should focus more on the interaction between 
them [8].
Reports indicate the combination treatment with 
BMSC and pharmacological agent is superior to any sin-
gle treatment method. For example, Simvastatin treat-
ment had been found to enhance neurogenesis and 
angiogenesis after stroke [9], and BMSC combined with 
Simvastatin could significantly facilitate BMSCs differ-
entiation into endothelial cells and improve arteriogen-
esis and angiogenesis, which was favorable to ameliorate 
functional outcome after cerebral ischemia [10–12].
Studies found that ferulic acid (FA) could improve neu-
rological function and decrease infarction size in middle 
cerebral artery occlusion (MCAo) rats through anti-oxi-
dative and anti-inflammatory effects, and it could also 
advance angiogenesis via increasing vascular endothelial 
growth factor (VEGF), platelet-derived growth factor and 
hypoxic-induced factor (HIF)-1α expressions in human 
umbilical vein endothelial cells [13, 14]. Our previous 
studies also suggested that sodium ferulate (SF, sodium 
salt of FA) combined with BMSC administration further 
decreased rat brain ischemic injury and increased neuro-
genesis at the 3rd day after ischemic stroke [16, 17]. As an 
alkylphthalide, n-butylidenephthalide (BP) could inhibit 
lipopolysaccharide-induced productions of nitric oxide, 
tumor necrosis factor-α and interleukin-1β from rat 
brain reactive microglia, thus contributing to the home-
ostasis of inflammatory mediation [15]. BP also had the 
capacities of keeping embryonic stem cell pluripotency 
by activating Jak2/Stat3 pathway and enhancing induced 
pluripotent stem cell (iPSc) generation efficiency [18]. 
SF and BP are active components from Radix Angelica 
Sinensis, and both of them suggest beneficial effects on 
stroke pathological processes. To investigate if SF and BP 
combined with BMSC could further advance angiogen-
esis and neurogenesis in rat ischemic stroke, we designed 




SF and BP were obtained from Shanghai Institute of 
Materia Medica, Chinese Academy of Sciences. GIBCO® 
Dulbecco’s modified Eagle medium/F12 (DMEM/
F12) was product of Life Technologies (USA). Primary 
antibodies for CD90-PE, CD45-FITC, CD34-PerCP 
were from Santa Cruz (California, USA). 2,3,5-triph-
enyltetrazolium chloride (TTC), MTT and Simvasta-
tin were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Primary antibodies of VEGF, von Willebrand fac-
tor (vWF), brain derived neurotrophic factor (BDNF) 
and neuronal class III β-tubulin (Tuj1) were products 
of Abcam (Cambridge, UK). Avidin–biotin peroxidase 
complex (ABC) kit and 3,3′-diamino-benzidine (DAB) 
kit were from Zymed Laboratories Inc (California, USA). 
Primary antibodies of AKT, p-Akt, mTOR and p-mTOR 
were obtained from Cell Signaling Technology, Inc. (Dan-
vers, USA). The other materials and reagents were from 
commercial sources.
Primary culture of BMSC and identification
BMSCs were obtained and cultured as our previous 
report [16]. Briefly, the cells were harvested aseptically 
from bone marrow of the tibias and femurs in 50–60  g 
male Sprague–Dawley (SD) rats and cultured with 
DMEM/F12 cell medium supplemented with 10  % fetal 
bovine serum and 1  % penicillin–streptomycin in a cell 
culture flask at 37 °C and 5 % CO2. New culture medium 
was replaced once every 48 h. The cells were digested and 
passaged with 0.25 % trypsin (HyClone) during cell loga-
rithm growth period with the cell fusion of 80 %.
To evaluate the BMSC purity, flow cytometry (Becton, 
Dickinson and Company, USA) was performed to identify 
CD90, CD45 and CD34 surface markers of cultured cells. 
The cells from passage 3 were collected and fixed with 
4 % paraformaldehyde for 5 min and washed with 0.1 M 
phosphate-buffered saline (PBS). After that, they were 
adjusted to the density of 1 ×  107/ml and were respec-
tively incubated with fluorescence-conjugated antibodies 
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including CD90-PE, CD45-FITC, CD34-PerCP and PBS 
(negative control) in a black chamber at 4 °C for 30 min. 
After washing with PBS, the cells were analyzed by a flow 
cytometer equipped with the Cellquest system (Becton, 
Dickinson and Company, USA).
The establishment of permanent middle cerebral artery 
occlusion model and experimental group definition
The study conforms to the National Institute of Health 
Guide for the Care and Use of Laboratory Animals (NIH 
Publications No. 80-23) revised in 1996 for scientific pur-
poses. All experimental procedures were approved by the 
Institutional Animal Care and Use Committee of Macau 
University of Science and Technology. Adult male SD rats 
(Guangdong Medical Laboratory Animal Center, Foshan, 
Guangdong, China) weighing 240–260 g were used in all 
experiments. Permanent middle cerebral artery occlu-
sion (pMCAo) was established according to our previous 
method [16]. In brief, the rats were anaesthetized with 
10 % (w/v) chloral hydrate (3.0 ml/kg, i.p.) and their body 
temperature was maintained at 40  °C by animal heat-
ing pad. 4–0 surgical nylon suture (length of 20–22 mm 
determined by body weight) coated with polylysine was 
inserted into the lumen of the right common carotid 
and advanced into the internal carotid artery until it 
obstructed the origin of the middle cerebral artery. 
Finally, the neurological function was evaluated using 
a 5-point scale neurological deficit score as reported by 
Longa and colleagues [19]. Only animals with the score 
of 2–3 were selected for the subsequent studies (0 = no 
deficit, 1 = failure to extend left paw, 2 = circling to the 
left, 3 = falling to the left, 4 = unable to walk spontane-
ously and consciousness). Sham operated animals under-
went the same surgery but without nylon suture inserted.
One hundred and twenty MCAo rats were randomly 
divided into 5 groups (24 rats per group), including 
MCAo group, BMSC group, Simvastatin (Sim) + BMSC 
group (as positive control), SF  +  BP group and 
SF + BP + BMSC group. One millilitre of PBS or BMSC 
suspension solution (2  ×  106 cells/ml) was intrave-
nously injected into MCAo, SF  +  BP or BMSC alone, 
Sim + BMSC and SF + BP + BMSC groups via caudal 
vein at 3 h after operation; and 1 ml of PBS or SF (60 mg/
kg) was intraperitoneally injected into MCAo, BMSC, 
Sim + BMSC group or SF + BP and SF + BP + BMSC 
groups once a day for continuous 7 days, the dosage SF 
were determined according to our previous report [17]; 
Simvastatin (1 mg/kg) [10] was gavaged daily for 7 days in 
Sim + BMSC group and BP (10 mg/kg) was subcutane-
ously injected into SF + BP and SF + BP + BMSC groups 
once a day for continuous 3 days respectively, the ratio of 
SF and BP dosage was defined according to preliminary 
experimental result (see Additional file 1).
TTC staining
To observe the volume of infarction zone in rat brain on 
the 7th day after treatment, TTC staining was applied. 
Rats (n  =  5) in each group were deeply anaesthetized 
with 10  % (w/v) chloral hydrate, and the brains were 
removed quickly and placed at −20  °C for 15  min, sec-
tions of 2.0  mm thickness were cut and stained with 
2 % solution of TTC at 37 °C for 30 min. The cross-sec-
tional area of each slice in infarcted brain was measured 
using image analysis software (Image-Pro Plus Ver-
sion 6.0, USA). The infarction volume was calculated by 
the corrected infarct volume (CIV). The formula: CIV 
(%)  =  [contralateral hemisphere volume−(ipsilateral 
hemisphere volume−infarct volume)]/contralateral hem-
isphere volume × 100 [20].
Immunofluorescence staining
On the 7th day after ischemic stroke, rats (n = 6) in each 
group were anaesthetized with 10  % chloral hydrate. 
Brains were fixed by transcardial perfusion with saline, 
followed by perfusion and immersion in 4 % paraformal-
dehyde. Fresh frozen sections of 5 μm thickness were cut 
on a cryostat microtome (Thermo fisher Scientific Shan-
don Cryotome FSE). Every 5th coronal section for a total 
of 6 sections was used for immunofluorescence stain-
ing. Prior to all staining procedures, tissue slices were 
extensively rinsed with 0.02 M PBS and blocked with 5 % 
normal goat serum in 0.02 M PBS containing 0.3 % Tri-
ton X-100 for 1  h. To identify the expressions of VEGF 
and BDNF in the IBZ, the slices incubated with rabbit 
primary antibodies to VEGF (1:50) and BDNF (1:200) 
at 4  °C overnight, followed by secondary antibodies to 
Alexa Fluor 488 labeled goat anti-rabbit IgG (H  +  L) 
(Life Technologies, USA) at 37  °C for 1  h. Nuclei were 
finally stained with 4′,6-diamidino-2-phenylindole in 
all images. The slices were visualized and digitally pho-
tographed with a confocal laser scanning microscope 
(Zeiss LSM710, Germany), 5 non-overlapping fields of 
one slice were randomly observed under a magnification 
of 10 × 40 in confocal images. To quantitatively analyze 
the proteins expression, Image-Pro Plus software was 
applied.
Histological and immunohistochemical staining
Rat brains (n = 6) were fixed with 4 % paraformaldehyde, 
and embedded in paraffin and cut into a series of 6 μm 
thick sections. For a morphological analysis of vessels 
and newborn neurons, samples were rinsed with Dulbec-
co’s phosphate buffered saline (Sigma, USA) containing 
0.01  % Tween-20 and immersed in 3  % H2O2/methanol 
for 15  min to inhibit endogenous peroxidase activity. 
Subsequently, brain sections were incubated with 10  % 
normal goat serum for 20 min at room temperature, and 
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then incubated with primary antibodies against vWF 
(1:100) and Tuj1 (1:200) at 4 °C for overnight. Following 
incubation with secondary antibody and ABC kit, sec-
tions were colored with DAB kit, and then stained with 
hematoxylin as a counterstain. Five slides were taken 
from each brain and each slide was randomly chose 5 
non-overlapping fields to observe the expressions of vWF 
and Tuj1 under BX51 microscopy (Olympus, Japan). 
The determinant of vascular density was assessed by the 
number of positive vWF-vessels/mm2 using the Aperio 
ImageScope 12.3 (Leica), simultaneously vWF positive 
vascular perimeter and Tuj1 expression were quantified 
using Image-Pro Plus software in IBZ.
MTT assay and experimental group divided in vitro
In order to find the optimal dosage of SF and BP treat-
ment for BMSC, the cells (1 × 105 cells/ml) were seeded 
in 96-well plates and incubated with different concentra-
tions of SF (400, 200, 100, 50, 25, 5, 1, 0.1 and 0.01 μg/ml), 
BP (4, 2, 1, 0.75, 0.5, 0.25, 0.125, 0.01 and 0.001 μg/ml) for 
48 h. According to the results, we found the SF concen-
tration of 1 μg/ml and the BP concentration of 0.75 μg/
ml had significant capacities of enhancing the viability of 
BMSCs, subsequently, we set the different concentrations 
of SF (50, 40, 20, 15, 10, 5 and 1 μg/ml) combined with 
BP (0.75 μg/ml) to incubate with BMSCs for 48 h. Prior 
to each assay, culture medium in each well was replaced 
by 100  μl fresh medium containing 10  μl of 5  mg/ml 
MTT stock solution. After 4 h of labeling cells with MTT, 
medium was removed and replaced with 100  μl DMSO 
in each well for 10  min at 37  °C. Samples were mixed 
and absorbance was set at 540 nm by using an enzyme-
linked immunosorbent assay reader [18]. Twelve repli-
cated wells were included in each group, and means were 
calculated. Finally, when we decided the optimal dos-
age of SF combined with BP treatment for BMSC, four 
groups were established which included normal group as 
control, SF (5 μg/ml) group, BP (0.75 μg/ml) group and 
SF + BP group.
Western blot analysis
Western Blot assay was conducted according to our pre-
viously described method [17]. The protein samples came 
from four groups’ BMSCs incubated with different thera-
peutic agents after 24  h in  vitro and cortex of ischemic 
hemisphere of each group (n = 7) on the 7th day after the 
operation in  vivo, and protein concentration was deter-
mined by enhanced BCA protein assay Kit (Beyotime 
Institute of Biotechnology, Shanghai, China). The sam-
ples were electrophoresed on sodium dodecyl sulphate–
polyacrylamide gel and electrophoretically transferred to 
PVDF membranes in Tris–glycine transfer buffer. Then, 
membranes were blocked with 5 % (w/v) instant non-fat 
dried milk for 1  h at room temperature, and incubated 
with rabbit primary antibodies corresponding to β-actin 
(internal control) (1:1000), VEGF (1:1000), BDNF (1:100), 
AKT (1:1000), p-AKT (1:2000), mTOR (1:1000) and 
p-mTOR (1:1000) at 4 °C overnight. The membranes were 
subsequently washed with TBST [50 mM Tris–HCl (pH 
7.4), 150 mM NaCl, 0.05 % Tween 20] and then incubated 
with secondary goat anti-rabbit IgG (H + L) (1:5000; LI-
COR, USA) for 1 h at room temperature. The bands were 
visualized with Odyssey Infrared Imaging System (LI-
COR, USA). The expressions of VEGF and BDNF were 
normalized against that of β-actin, phosphorylated levels 
of AKT and mTOR were analyzed by total levels of cor-
responding protein. The assay was replicated for three 
independent times.
Statistical analysis
Statistical calculations were performed with Statistical 
Product and Service Solutions (SPSS) (version 17.0, Chi-
cago, IL, USA) by one-way analysis of variance followed 
by least significant difference test for multiple compari-
sons. Data were expressed as mean ± standard deviation 




As shown in Fig. 1, from the primary cultured BMSCs to 
passage 1, the morphology of adherent cells seemed to be 
fibroblastic-like mononuclear cells and took a logarithm 
growth appearance. In the present study, the cells at pas-
sage 3 were used to determine the purity by flow cytome-
try. Report demonstrated that CD90 (Thymocyte antigen 
1, Thy-1) is a BMSC surface marker [21], while CD45 and 
CD34 are hematopoietic cell markers [22]. The respective 
percentage for expression of CD45 and CD34 was 1.2 and 
0.3 %, whereas CD90 positive rate was as high as 98.7 %. 
This result showed that the derived BMSCs was with 
high-purity and could be applied for next study.
SF and BP combined with BMSCs decreased infarction zone 
after stroke
To directly observe the brain infarction zone in each 
group, TTC staining was used. As shown in Fig.  2, 
On the 7th day after operation, the infarct volumes in 
SF + BP + BMSC group (9.93 ± 0.08 %), Sim + BMSC 
(13.56  ±  0.09  %), BMSC group (18.22  ±  0.02  %) and 
SF + BP group (19.72 ± 0.07 %) were significantly smaller 
than that of MCAo group (27.99 ± 0.08 %) (p < 0.01, vs. 
SF  +  BP  +  BMSC and Sim  +  BMSC group; p  <  0.05, 
vs. BMSC group and SF + BP group). Furthermore, the 
infarct volume in SF  +  BP  +  BMSC group was nota-
bly reduced in comparison with BMSC and SF  +  BP 
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groups (p  <  0.05), but there was no statistical differ-
ence between the infarction areas in SF + BP + BMSC 
and Sim  +  BMSC group. No obvious injury area was 
observed in sham operated group according to the TTC 
staining. The above results suggested SF and BP com-
bined with BMSC were capable of decreasing infarct vol-
ume post-stroke.
SF and BP combined with BMSC enhanced VEGF and BDNF 
expressions in the IBZ
As an important angiogenic factor, VEGF plays pri-
mary role in facilitating angiogenesis. The quantitative 
analysis of fluorescent immunostaining image in the 
IBZ suggested the expressions of VEGF in BMSC alone, 
Sim + BMSC, SF + BP and SF + BP + BMSC group were 
more significant than that in MCAo group (p < 0.01), and 
both SF + BP + BMSC and Sim + BMSC treatment could 
obviously improve VEGF expression compared with 
BMSC alone treatment and SF  +  BP group (p  <  0.01). 
Although VEGF expression in SF + BP + BMSC group 
was higher than that in Sim + BMSC group, there was no 
statistical significance (Fig. 3a, b).
It reported that hydrogel-BDNF advanced imma-
ture neurons migration to IBZ and kept them survival 
for a long time, as well as facilitated axonal sprout-
ing following stroke [23]. Our immunofluorescence 
assay in Fig.  3c, d suggested the BDNF expression in 
SF  +  BP  +  BMSC group was the most distinguished 
in all groups (p  <  0.01, vs. MCAo, SF  +  BP, BMSC 
and Sim  +  BMSC group), and the expression in 
Sim  +  BMSC group was notably higher than those in 
BMSC alone and SF  +  BP group (p  <  0.01). It illus-
trated that SF + BP + BMSC group could dramatically 
improve BDNF expression in the IBZ.
Fig. 1 BMSC morphology and phenotype identification by flow cytometry. After the initial seeding, the morphology of adherent cells seemed to 
be fibroblastic-like mononuclear cells and took a logarithm growth appearance; from passage 1, the cells became uniform and grow in whirlpool, 
radial, or parallel patterns (Magnification, ×100). BMSCs from passage 3 were incubated with fluorescence-conjugated antibodies including CD90-
PE, CD45-PerCP, CD34-PerCP and PBS. The positive expression of CD90 was 98.7 %, and negative identifications of CD45 and CD34 were 1.2 and 
0.3 %, respectively
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SF and BP combined with BMSC increased angiogenesis 
and neurogenesis in the IBZ
During the assay of angiogenesis, we observed vWF posi-
tive vascular perimeter and the number of positive vWF-
vessels in the IBZ by immunohistochemical staining 
(Fig. 4a, b, c). The results suggested that the two groups 
of SF + BP + BMSC and Sim + BMSC could more obvi-
ously enhance vascular perimeter and density than those 
in BMSC, SF  +  BP and MCAo groups (p  <  0.01, vs. 
MCAo, p  <  0.05, vs. SF +  BP group and BMSC alone). 
Although the effects of SF  +  BP  +  BMSC group on 
vWF-positive perimeter and density were higher than 
Sim  +  BMSC group, there was no statistical differ-
ence between them. It illustrated that SF + BP + BMSC 
group had the same capable of promoting angiogenesis as 
Sim + BMSC group in the IBZ post-stroke.
Fig. 2 Infarction volume analysis on the 7th day after ischemic stroke. TTC staining of brain slices in Sham, MCAo, BMSC, SF + BP, Sim + BMSC 
and SF + BP + BMSC groups were presented, and infarction volume in each group was analyzed. Data are presented as mean ± SD. *p < 0.05, 
**p < 0.01, vs MCAo group, #p < 0.05, vs BMSC group, $p < 0.05, vs SF + BP group
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In order to further demonstrate the combination 
therapeutic effect on neurogenesis, Tuj1 was deter-
mined. As a marker of immature neurons, quan-
titative analysis indicated that SF  +  BP  +  BMSC, 
Sim + BMSC, BMSC and SF + BP groups could obvi-
ously elevate Tuj1 expression in comparison with 
MCAo group (p  <  0.01), and Tuj1 expressions in 
Sim  +  BMSC group was higher than that in BMSC 
group, but there was no significant difference between 
the two groups. Additionally, SF  +  BP  +  BMSC 
group could notably promote Tuj-1 expression com-
pared with Sim +  BMSC group (p  <  0.05, Fig.  4d, e). 
Moreover, we also test doublecortin (DCX, a micro-
tubule-associated protein expressed by neuronal pre-
cursor cells and immature neurons) expression in 
ischemic hemisphere by western blot, it suggested 
SF (60  mg/kg)  +  BP (10  mg/kg)  +  BMSC group sig-
nificantly improved DCX expression compared with 
Sim + BMSC group and BMSC alone (p < 0.05, see in 
Additional file 1). The above results demonstrated that 
SF and BP combined with BMSCs advanced neuro-
genesis, whose effect was superior to simvastatin plus 
BMSC administration.
The definition of optimal dosages of SF and BP treatment 
for BMSCs in vitro
MTT assay was used to identify BMSC viability follow-
ing different dosages of SF, BP and SF +  BP treatment. 
According to results from the tests, we found that SF at 
dosage of 1  μg/ml and BP at dosage of 0.75  μg/ml had 
the most obvious capacities to improve the viability of 
BMSCs (Fig. 5a, b). In the MTT assay of seven concentra-
tions of SF combined with BP (0.75  μg/ml) for BMSCs, 
the results indicated that cell survival rates significantly 
increased at the SF dosage of 5 μg/ml on the 48 h post-
treatment (Fig. 5c). Therefore, we finally selected the SF 
dosage of 5 μg/ml and BP dosage of 0.75 μg/ml as optimal 
dosages for next experiment in vitro.
SF and BP administration triggered BMSCs to express VEGF 
and BDNF
Western Blot analysis was used to quantify the pro-
tein expression levels of VEGF and BDNF derived from 
BMSCs at 24 h. Figure 6 showed that VEGF and BDNF 
expressions in SF + BP group were significantly high in 
comparison with control, SF and BP groups. The above 
results illustrated that combination of SF and BP might 
Fig. 3 SF and BP combined with BMSC promoted VEGF and BDNF expressions after ischemia. a, c Immunofluorescence staining images with VEGF 
and BDNF (green) were presented and positive signals were analyzed (b, d). Data are expressed as mean ± SD. **p < 0.01, compared with MCAo 
group, ##p < 0.01, compared with BMSC group, $$p < 0.01, compared with SF + BP, &&p < 0.01, compared with Sim + BMSC group. The experiment 
was repeated for 3 times, and representative pictures are shown. Scale bar 20 μm
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have an additive effect on the improvement of VEGF and 
BDNF expressions in BMSCs.
SF and BP combined with BMSC activated AKT/mTOR 
signaling pathway after cerebral ischemia
AKT/mTOR signaling pathway plays a critical role in pro-
moting angiogenesis and neurogenesis. Some research 
suggested that regulating the activity of mTOR should be 
developed as a potential therapeutic strategy for ischemic 
stroke [24]. To test whether our combination treatment 
of therapeutic agents and BMSC can influence ischemic 
cortical AKT/mTOR signaling pathway post-stroke, 
we applied western blot assay. As depicted in Fig. 7, the 
phosphorylated expressions of AKT in SF + BP + BMSC 
and Sim  +  BMSC groups were obviously high com-
pared with those in BMSC, SF + BP and MCAo groups 
(p  <  0.01); Meanwhile, quantitative analysis indicated 
the tendency of mTOR expression in each group was 
Fig. 4 SF and BP combined with BMSC enhanced angiogenesis and neurogenesis after ischemia. a, d Immunohistochemistry staining images of 
vWF-vessles and Tuj1 were presented, vWF positive vascular perimeter and density, as well as relative expression of Tuj1 were quantitated (b, c, e). 
Data are expressed as mean ± SD. **p < 0.01, compared with MCAo group, #p < 0.05, ##p < 0.01, compared with BMSC group, $p < 0.05, $$p < 0.01, 
compared with SF + BP, &p < 0.05, compared with Sim + BMSC group. The experiment was repeated for 3 times, and representative pictures are 
shown. Scale bar 50 μm
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parallel with AKT phosphorylation. It should be noted 
that SF +  BP and BMSC groups had the capabilities of 
up-regulation of AKT/mTOR expression in compari-
son with MCAo, but there was no statistics difference 
between SF + BP and MCAo groups.
Discussion
Evidences have showed that grafted BMSCs could 
improve angiogenesis and neurogenesis which contrib-
ute to neurological functional recovery, and the com-
bination treatment of BMSCs and therapeutic drug is 
further beneficial to the restoration of stroke. However, 
the debate always existed because the limited number 
of BMSCs in brain is not parallel with their effects on 
the amelioration of neurological function. In the pre-
sent study, we observed that SF and BP combined with 
BMSC notably improved angiogenesis and neurogen-
esis in IBZ after ischemic stroke. The synergistic effects 
were not only related to the enhancement of VEGF and 
BDNF expressions by SF and BP, as well as BMSC admin-
istrations respectively, but also associated with SF and 
BP advancing BMSC to secrete VEGF and BDNF; mean-
while, the mechanism of the combination treatment 
might attribute to up-regulating AKT/mTOR signal path-
way (Fig. 8).
Amounts of studies have demonstrated that BMSC 
administration could enhance angiogenesis and neuro-
genesis; in this sense, BMSC transplantation has been 
recognized as an effective method for the treatment of 
stroke [5, 6, 25, 26]. Though the defined mechanism of 
BMSCs treatment for stroke is still ambiguous, most of 
experimental results suggested the therapeutic effects 
was probably relevant to BMSCs paracrine function 
which would secrete different types of trophic factors 
resulted in synaptogenesis and neurogenesis, as well as 
angiogenesis [26, 27]. Previously, Cui and colleagues 
[10] demonstrated the combination treatment of Sim-
vastatin and BMSC could facilitate BMSCs migration 
Fig. 5 MTT assay for optimal dosages of SF + BP treatment for BMSCs in vitro. BMSCs (1 × 105 cells/ml) were respectively incubated with different 
concentrations of SF, BP, SF + BP in 96-well plates for 48 h, and the absorbance at 540 nm in every plate was recorded. The viabilities of Cells (a, b 
and c) were expressed as the percentage of untreated control in the function of different concentrations of SF, BP, SF + BP. We finally selected the SF 
dosage of 5 μg/ml and the BP dosage of 0.75 μg/ml for next experiment in vitro according to the experimental result
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into ischemic area, enhance angiogenesis and ame-
liorate neurological functional outcome after stroke, 
and these effects were superior to either Simvastatin or 
BMSC alone treatment. Our previous study also demon-
strated that SF combined with BMSC not only decreased 
ischemic penumbral injury, but also increased endog-
enous neurogenesis post-stroke [17], so we speculated 
the model of combination treatment might be a more 
potential therapeutic method for ischemic stroke due 
to synergic functions of supplementary approaches. In 
the present study, we choose SF and BP combined with 
BMSC as a dominant treatment model for stroke based 
on previous results of SF on BMSC and BP on iPSc [15–
18]. In order to define optimal dosage ratio of SF and BP 
in  vivo, we tested VEGF, DCX expressions of ischemic 
hemisphere, as well as neurological functional outcome 
in different dosages of SF and BP combined with BMSC 
groups, BMSC alone group and Sim + BMSC group, fol-
lowed by multiple comparisons in our preliminary exper-
iment, and finally confirmed that the valid dosage ratio of 
SF and BP was 6:1 (see Additional file 1).
Initial studies have suggested that the occurrences of 
angiogenesis and neurogenesis are not detached, yet they 
are coupled processes after stroke [8, 28]. Angiogenesis 
primarily enhanced oxygen, neurotrophic factors, NSCs 
migration and nutrient supply to the injured tissue, as 
well as removed necrotic debris; In addition, cerebral 
endothelial cells (ECs) from stroke could facilitate NSCs 
proliferation and differentiation into neurons [7, 28–30]. 
On the other hand, Teng reported that NSCs from the 
ischemic subventricular zone could increase capillary 
tube formation and the coupling of angiogenesis and 
neurogenesis was substantially regulated by VEGF [28]. 
As an angiogenic protein, VEGF had exhibited the effects 
of neuroprotection, angiogenesis and neurogenesis after 
cerebral ischemia [31]. Furthermore, it had been demon-
strated that BMSCs could release VEGF, and simvastatin 
could further increase BMSCs differentiation into ECs 
and tube formation through the improvement of VEGF 
receptor; in this sense, BMSCs treatment will result in 
angiogenesis post-stroke via mediating VEGF expres-
sion [10, 11, 32]. In our present study, SF + BP + BMSC 
administration dramatically promoted VEGF expression 
in the IBZ, and the effect was the same as Sim + BMSC 
group. BDNF played a critical role in promoting the syn-
aptic and axonal plasticity, as well as stimulating human 
umbilical cord blood-derived mesenchymal stem cells 
differentiation into neurons after focal ischemia [33, 34]. 
Additionally, Fouda and colleagues [35] found knock-
down BDNF in animal stroke model notably decrease 
cerebral vascular density, and it suggested BDNF also 
had important angiogenic function. Our present study 
found SF + BP + BMSC administration could more dis-
tinctly promote BDNF expression in comparison with 
Fig. 6 BMSC derived -VEGF and BDNF expressions by western blot assay. Western blot tested the expressions of BMSC derived-VEGF and BDNF in 
four groups (control, SF, BP and SF + BP group). Representative western blot results for VEGF and BDNF and quantitative analysis at 24 h after treat-
ment. Data are expressed as mean ± SD. **p < 0.01, vs control group, #p < 0.05, ##p < 0.01, vs SF group, &&p < 0.01, vs BP group
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other four groups; especially, the action was superior 
to Sim  +  BMSC group. Moreover, our present study 
firstly confirmed that the combination of SF and BP 
could promote BMSCs to synthesize VEGF and BDNF 
in  vitro, and the therapeutic effect was greater than SF 
or BP alone treatment. So we think the additive effects 
of the improvement of VEGF and BDNF expressions in 
SF  +  BP  +  BMSC group attribute to three aspects, it 
includes SF and BP treatment, BMSC treatment respec-
tively, as well as SF plus BP advancing BMSC autocrine 
action.
To evaluate the capacities of angiogenesis and neu-
rogenesis in different groups, we test vWF-vessel den-
sity and vascular perimeter, as well as Tuj-1 expression. 
The results suggested vWF-vessel density and vascu-
lar perimeter had not significant difference between 
SF +  BP +  BMSC and Sim +  BMSC groups, although 
the two groups had more distinctly abilities of enhanc-
ing angiogenesis in comparison with BMSC and 
SF  +  BP groups. As a newborn neuron marker, Tuj-1 
is always used to reflect neurogenesis in the study of 
stroke [36]. Our results showed that Tuj-1 expression in 
SF + BP + BMSC group was the highest. Though study 
suggested statin was capable of increasing neurogen-
esis, synaptic protein and synaptophysin after stroke [9], 
Simvastatin combined with BMSC in the present study 
did not obviously promote neurogenesis compared with 
BMSC treatment. In present study, we did not use VEGF 
and BDNF siRNA expression vectors or blockage of their 
receptors to test whether the effects of angiogenesis and 
neurogenesis were suppressed, but based on previous 
researches on the actions of VEGF and BDNF post-stroke 
[28, 31–35), we concluded that the therapeutic effect of 
SF and BP combined with BMSC on angiogenesis and 
neurogenesis might relate to the enhancement of VEGF 
and BDNF expressions in IBZ. According to the analy-
sis of VEGF and BDNF expressions in SF + BP + BMSC 
group compared with those in Sim +  BMSC group, we 
think the improvement of BDNF by SF an BP combined 
with BMSC should more contribute to neurogenesis 
rather than angiogenesis; it is consistent with Jiang and 
colleagues’ conclusion [37].
In order to further explore the potential mecha-
nism, we detected AKT/mTOR signaling pathway by 
Fig. 7 SF and BP combined with BMSC activated AKT/mTOR signaling pathway post-stroke. a Representative western blot results for p-Akt, t-Akt, 
p-mTOR and t-mTOR in the cortex of ischemic hemisphere of five groups were shown; b quantitative analysis was presented. Data are expressed as 
mean ± SD. *p < 0.05, **p < 0.01, compared with MCAo group, ##p < 0.01, compared with BMSC group, $p < 0.05, $$p < 0.01, compared with SF + BP 
group
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Western Blot. Previous reports had demonstrated that 
VEGF interacted with its receptors on the cellular mem-
brane and phosphorylated AKT, subsequently activated 
mTOR, then up-regulated VEGF expression, and finally 
improved angiogenesis against cerebral ischemia [38, 
39]; recent reports indicated that BDNF could bind with 
Tropomyosin receptor kinase B receptor and then acti-
vate AKT/mTOR signaling pathway which will result in 
neuroprotective effects, and was beneficial to maintain 
the endogenous neuronal progenitor pool and regu-
late new neuron development after stroke [23, 40–43]. 
Additionally, the activated BDNF/AKT/mTOR signaling 
Fig. 8 Mechanisms of SF and BP combined with BMSC administration on angiogenesis and neurogenesis following stroke. The effective mecha-
nisms of the combination treatment on angiogenesis and neurogenesis not only include up-regulating VEGF and BDNF-AKT/mTOR signals by 
SF + BP, as well as BMSC treatments respectively, but also associate with the enhancement of BMSC derived-VEGF and BDNF expressions by SF + BP 
and subsequently activating AKT/mTOR pathway in cerebral parenchymal cells. Moreover, triggering BMSC paracrine function further improves the 
additive effects of the combination treatment on angiogenesis and neurogenesis after ischemia
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pathway also increased the number of cells in the hip-
pocampal dentate gyrus, as well as established a positive 
feedback loop of BDNF productions following the activa-
tion of mTOR by ketamine [44, 45]. Therefore, activated 
VEGF and BDNF-AKT/mTOR pathway played impor-
tant roles in angiogenesis and neurogenesis post-stroke. 
Through quantitative analysis of phosphorylated AKT 
and mTOR, as well as VEGF and BDNF expressions of 
each group in vivo and vitro, we thought the effects of the 
enhancement of VEGF and BDNF-AKT/mTOR cascade 
in SF + BP + BMSC group not only attributed to SF and 
BP, BMSC treatments respectively, but also associated 
with SF and BP advancing BMSC function transposed via 
non-cell-autonomous signaling. Evidence indicated intra-
venous injection of BMSCs mainly exist in peripheral 
organs (lungs, spleen, liver) of MCAo model rather than 
brain [46], so present consensus has been considered 
that the amelioration of neurological function of BMSCs 
is related to their paracrine function, instead of engraft-
ment into the infarction zone. In our study, the up-regu-
lation of BMSC paracrine function embodied that SF and 
BP triggered BMSCs to synthesize VEGF and BDNF, sub-
sequently AKT/mTOR cascade was activated in cerebral 
parenchymal cells. It contributed to promoting angio-
genesis and neurogenesis in the IBZ, for the reason that 
we deemed SF and BP should be a “Trigger point”. Inter-
estingly, AKT/mTOR expression in SF  +  BP  +  BMSC 
group was higher than that in Sim  +  BMSC group, it 
might be explained why SF + BP + BMSC group could 
more notably amplify neurogenesis in comparison with 
Sim  +  BMSC group. Our present study also suggested 
that SF and BP combined with BMSC could distinctly 
reduce infarction volume which perhaps attributed to 
the improvement of angiogenesis and neurogenesis after 
ischemia. However, there are limitations in the cur-
rent study. First, we did not know if there was an addi-
tive role between VEGF and BDNF on angiogenesis and/
or neurogenesis by the combination treatment. Second, 
the specific effect and mechanism of SF and BP advanc-
ing BMSC paracrine function on which type of cerebral 
parenchymal cells (e.g. astrocytes, neurons, ECs) should 
be illustrated in  vitro. Third, the effects of SF and BP 
combined with BMSC on angiogenesis and neurogenesis 
should not only attribute to the improvement of VEGF 
and BDNF, as pluripotent cells, BMSCs are sure to have 
other mechanisms, it needs to be further explored fol-
lowing experiments.
Conclusion
In summary, our present study firstly demonstrates that 
SF and BP combined with BMSC can improve angiogen-
esis and neurogenesis in IBZ and decrease lesion volume 
post-stroke. The therapeutic effects are associated with 
the activation of VEGF and BDNF-AKT/mTOR signal 
pathway. Moreover, SF and BP triggering BMSC paracrine 
function would more specifically address synergistic effi-
ciency of the combination treatment on ischemic stroke.
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